Subsequent Hip Fracture in Osteoporotic Hip Fracture Patients
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: A significant number of patients who have experienced previous surgical treatment for an osteoporotic hip fracture experience a subsequent hip fracture (SHF) on the opposite side. This study aims to analyze the risk factors and the correlation between osteoporosis and SHF on the opposite side in order to assess the usefulness of bisphosphonate treatment for the prevention of SHFs. Materials and Methods: We included 517 patients treated from March 1997 to April 2009 in this study. The inclusion criteria included previous unilateral hip fracture, without osteoporotic treatment, and a T-score less than -3.0 at the time of the fracture. We studied these patients in terms of death, SHF, alcoholism, living alone, dementia, dizziness, health status, osteoporotic treatment after fracture and bone mineral density (BMD). In total, 34 patients experienced a SHF. We selected another 34 patients without a SHF who had similar age, sex, body mass index, BMD, diagnosis, treatment and a follow up period for a matched pair study. We compared these two groups. The average follow up was 8.3 years and 8.1 years, respectively. Results: The mortality rate of the 517 patients was 138 (27%). The BMD at the time of fracture demonstrated no statistical difference between the two groups (p>0.05). Nine patients (26%) within the SHF group were prescribed Risedronate and 18 patients (53%) received the same treatment in the non-SHF group. There was a statistical relationship with the treatment of osteoporosis (p=0.026). The average BMD of patients with SHF was -5.13 and -5.02 in patients without SHF was (p>0.05). Conclusion: Although primary surgical treatments are important for an excellent outcome in osteoporotic hip fractures, treatment of osteoporosis itself is just as important for preventing SHFs.
Abstract
Purpose: A significant number of patients who have experienced previous surgical treatment for an osteoporotic hip fracture experience a subsequent hip fracture (SHF) on the opposite side. This study aims to analyze the risk factors and the correlation between osteoporosis and SHF on the opposite side in order to assess the usefulness of bisphosphonate treatment for the prevention of SHFs. Materials and Methods: We included 517 patients treated from March 1997 to April 2009 in this study. The inclusion criteria included previous unilateral hip fracture, without osteoporotic treatment, and a T-score less than -3.0 at the time of the fracture. We studied these patients in terms of death, SHF, alcoholism, living alone, dementia, dizziness, health status, osteoporotic treatment after fracture and bone mineral density (BMD). In total, 34 patients experienced a SHF. We selected another 34 patients without a SHF who had similar age, sex, body mass index, BMD, diagnosis, treatment and a follow up period for a matched pair study. We compared these two groups. The average follow up was 8.3 years and 8.1 years, respectively. Results: The mortality rate of the 517 patients was 138 (27%). The BMD at the time of fracture demonstrated no statistical difference between the two groups (p>0.05). Nine patients (26%) within the SHF group were prescribed Risedronate and 18 patients (53%) received the same treatment in the non-SHF group. There was a statistical relationship with the treatment of osteoporosis (p=0.026). The average BMD of patients with SHF was -5.13 and -5.02 in patients without SHF was (p>0.05). Conclusion: Although primary surgical treatments are important for an excellent outcome in osteoporotic hip fractures, treatment of osteoporosis itself is just as important for preventing SHFs.
참고문헌 (20)
- Melton LJ 3rd, "Perspective. How many women have osteoporosis?", J Bone Miner Res, 7, pp.1005~1010 (1992)
- Cooper C, "Hip fractures in the elderly: a world-wide projection", Osteoporos Int, 2, pp.285~289 (1992)
- Hodsman AB, "10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program", Arch Intern Med, 168, pp.2261~2267 (2008)
- 이성락, "고관절 주위골절로 인한 사망률 및 활동성 -전향적 연구-", 대한정형외과학회지, 40(4), pp.423~427 (2005), 대한정형외과학회
- Gardner MJ, "Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial", J Bone Joint Surg Am, 87, pp.3~7 (2005)
- Juby AG, "Evaluation of osteoporosis treatment in seniors after hip fracture", Osteoporos Int, 13, pp.205~210 (2002)
- Cummings SR, "Epidemiology of osteoporosis and osteoporotic fractures", Epidemiol Rev, 7, pp.178~208 (1985)
- Eastwood EA, "Patients with hip fracture: subgroups and their outcomes", J Am Geriatr Soc, 50, pp.1240~1249 (2002)
- Melton LJ, "Further characterization of the heterogeneity of the osteoporotic syndromes", Proceedings of the International Symposium on Clinical Disorders of Bone and Mineral Metabolism, pp.145~152 (1989), Mary Ann Liebert, Inc
- Boston DA., "Bilateral fractures of the femoral neck", Injury, 14, pp.207~210 (1982)
- Bell GH, "Variations in strength of vertebrae with age and their relation to osteoporosis", Calcif Tissue Res, 1, pp.75~86 (1967)
- Carter DR, "Bone compressive strength: the influence of density and strain rate", Science, 194, pp.1174~1176 (1976)
- Ryg J, "Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001", J Bone Miner Res, 24, pp.1299~1307 (2009)
- Cook PJ, "Fractured femurs, falls and bone disorders", J R Coll Physicians Lond, 16, pp.45~49 (1982)
- Jung ES, "Diffrences of bone mineral density between osteoporotic group with or without compression fracture of the spine", J Korean Soc Fract, 11, pp.629~633 (1998)
- 장작, "노년층 고관절부 골절과 골다공증의 상관 관계", Hip and Pelvis, 20(4), pp.299~304 (2008), 대한고관절학회
- Report of a WHO Study Group, "17. Assessment of fracture risk and its application to screening for postmenopausal osteoporosi", World Health Organ Tech Rep Ser, 843, pp.1~129 (1994)
- McClung MR, "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", N Engl J Med, 344, pp.333~340 (2001)
- Bilezikian JP., "Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis", Am J Med, 122(2 Suppl), pp.14~21 (2009)
- Kanis JA, "A meta-analysis of previous fracture and subsequent fracture risk", Bone, 35, pp.375~382 (2004)